Gossamer Bio, Inc. financial data

Symbol
GOSS on Nasdaq
Industry
Pharmaceutical Preparations
Location
3013 Science Park, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 634 % +16.4%
Debt-to-equity 738 % -83.3%
Return On Equity -526 % +86%
Return On Assets -62.7 % +24.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 226M shares +138%
Common Stock, Shares, Outstanding 226M shares +137%
Entity Public Float 98M USD -81.9%
Common Stock, Value, Issued 23K USD +130%
Weighted Average Number of Shares Outstanding, Basic 226M shares +138%
Weighted Average Number of Shares Outstanding, Diluted 226M shares +138%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 37.9M USD -17.2%
Operating Income (Loss) -178M USD +16.2%
Nonoperating Income (Expense) 5.2M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -180M USD +21.6%
Net Income (Loss) Attributable to Parent -173M USD +21.8%
Earnings Per Share, Basic -0.85 USD/shares +65.6%
Earnings Per Share, Diluted -0.85 USD/shares +65.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 38.9M USD -40.4%
Marketable Securities, Current 206M USD +50.4%
Assets, Current 255M USD +21.3%
Property, Plant and Equipment, Net 1.07M USD -69.5%
Operating Lease, Right-of-Use Asset 2.4M USD -54.1%
Other Assets, Noncurrent 613K USD -17.5%
Assets 259M USD +17.9%
Accounts Payable, Current 2.66M USD -2.6%
Employee-related Liabilities, Current 5.72M USD +5.52%
Accrued Liabilities, Current 14.6M USD -0.43%
Liabilities, Current 35.8M USD -11.7%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 233M USD -6.33%
Accumulated Other Comprehensive Income (Loss), Net of Tax -628K USD -44%
Retained Earnings (Accumulated Deficit) -1.25B USD -16%
Stockholders' Equity Attributable to Parent 26.7M USD
Liabilities and Equity 259M USD +17.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.3M USD +1.3%
Net Cash Provided by (Used in) Financing Activities -2.56M USD -0.75%
Net Cash Provided by (Used in) Investing Activities 61.7M USD +607%
Common Stock, Shares Authorized 700M shares 0%
Common Stock, Shares, Issued 226M shares +137%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.75M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 38.9M USD -40.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 367K USD -44.6%
Deferred Tax Assets, Valuation Allowance 221M USD +8.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 222M USD +7.92%
Operating Lease, Liability 2.65M USD -53.6%
Depreciation 1.6M USD -11.1%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -173M USD +21.8%
Lessee, Operating Lease, Liability, to be Paid 2.71M USD -55.2%
Property, Plant and Equipment, Gross 6.5M USD -35.6%
Operating Lease, Liability, Current 2.65M USD -13.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 144K USD -95.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 144K USD -95.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 66K USD -81.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 144K USD -91.7%
Deferred Tax Assets, Operating Loss Carryforwards 123M USD -4.65%
Unrecognized Tax Benefits 13.7M USD +29.2%
Operating Lease, Payments 3.1M USD -11.4%
Depreciation, Depletion and Amortization 1.4M USD -24.1%
Share-based Payment Arrangement, Expense 32.3M USD +191%
Interest Expense 13.1M USD -5.56%